Further updated data at a median follow-up of 5 years (of trastuzumab-containing neoadjuvant therapy followed by adjuvant trastuzumab) in patients with locally advanced or inflammatory BC highlight the association between a complete response and long-term outcomes of patients with HER2+ disease. This evidence concerns the gene ERBB2 and breast cancer.